Restoring Motor and Sensory Hand Function in Tetraplegia Using a Neural Bypass System

Sponsor
Chad Bouton (Other)
Overall Status
Recruiting
CT.gov ID
NCT03680872
Collaborator
(none)
3
1
1
68
0

Study Details

Study Description

Brief Summary

This is a single-cohort early feasibility trial to determine whether an investigational device called the Bidirectional Neural Bypass System can lead to the restoration of movement and sensation in the hand and wrist of up to three individuals with tetraplegia.

Condition or Disease Intervention/Treatment Phase
  • Device: Bidirectional Neural Bypass System
N/A

Detailed Description

This study consists of the following three phases: baseline visit, surgical procedure, and restoration sessions.

At the baseline visit, participants will undergo a medical history review, physical and neurological examination, functional assessment of motor and sensory capabilities, a functional magnetic resonance image (fMRI), diffusion tensor image (DTI), and a transcutaneous neuromuscular and transcutaneous spinal cord stimulation test.

Participants deemed eligible for continued participation will then undergo a craniotomy under anesthetic sedation to implant the investigational device. The surgeon will implant microelectrode arrays into the primary motor cortex to record neural activity associated with desired movements and into the primary somatosensory cortex to deliver stimulation in order to provide sensory perception.

While in surgical recovery, participants will have their vital signs monitored, be provided pain medication and antibiotics, and undergo a computed tomography (CT). The participants may also undergo electromyography and microneurography while in recovery. After being evaluated by a physician, the participants will be discharged from the hospital to continue their recovery.

After fully recovering, participants will attend restoration sessions at the Feinstein Institute for Medical Research's Center for Bioelectronic Medicine. Participants will attend up to 3 study sessions a week for approximately 12 months, with each session lasting up to 4 hours. The sessions will progressively focus on identifying neural activity related to desired movements, restoring volitional control of the hand and wrist, restoring tactile perception, and then restoring volitional control and tactile perception of the hand and wrist simultaneously.

During the sessions, participants will have brain signals recorded from electrodes implanted in the brain, receive transcutaneous electrical stimulation to the arm and/or spinal cord, and receive a small amount of electrical current to the electrodes implanted in the brain. The participants may also undergo electromyography and microneurography during some of the sessions.

The study will be considered complete after completion of enrollment (up to 3 participants), completion of study procedures by all participants, and the completion of analysis of identifiable study data.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
3 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
This is a single-cohort early feasibility trial to determine whether an investigational device called the Bidirectional Neural Bypass System can lead to the restoration of movement and sensation in the hand and wrist of up to three individuals with tetraplegia.This is a single-cohort early feasibility trial to determine whether an investigational device called the Bidirectional Neural Bypass System can lead to the restoration of movement and sensation in the hand and wrist of up to three individuals with tetraplegia.
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Restoring Motor and Sensory Hand Function in Tetraplegia Using a Neural Bypass System
Actual Study Start Date :
Sep 30, 2019
Anticipated Primary Completion Date :
Dec 1, 2024
Anticipated Study Completion Date :
Jun 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Spinal Cord Injury Participants

This group consists of individuals with tetraplegia receiving an investigational device called the Bidirectional Neural Bypass System.

Device: Bidirectional Neural Bypass System
These participants will receive the investigational device called the Bidirectional Neural Bypass System. The study intends to use this device to restore volitional movement and sensation to the hand and wrist of an individual during its use in the laboratory.

Outcome Measures

Primary Outcome Measures

  1. Restoration of Movement [The primary outcome will be assessed over the course of 12 months during the study's restoration sessions.]

    The primary outcome of restoring movement will be evaluated through Graded Redefined Assessment of Strength, Sensibility & Prehension. The performance will be graded on a numeric scale from 0-92, where a higher number indicates a better outcome. Participants will complete 10 distinct arm, wrist, and finger movements. The movements will be evaluated on a 5-point scale ranging from no movement to normal movement for a total of 0-50. Participants will be asked to perform a cylindrical grasp, key pinch, and a thumb-index pinch. The movements will be evaluated on a 4-point scale ranging from an inability to position wrist and fingers to able to perform movement with normal force for a total of 0-12. Participants will be asked to pour water, unscrew lids, place pegs on a board, open a lock, drop coins in a slot, and screw nuts. The movements will be evaluated on a 5-point scale ranging from 0% completed to 100% completed with expected grasp and no difficulties for a total of 0-30.

  2. Restoration of Sensation [The primary outcome will be assessed over the course of 12 months during the study's restoration sessions.]

    The primary outcome of restoring the perception of tactile sensation of the hand will be evaluated through the 5-Point Likert Scale. Participants will be asked whether they perceive sensation in response to objects being placed against the hand and fingertips. Participants will indicate whether they feel the object by selecting either strongly disagree (1), disagree (2), neutral (3), agree (4), or strongly agree (5). A higher total response score indicates an improvement in outcome.

Eligibility Criteria

Criteria

Ages Eligible for Study:
22 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Males and females between 22 and 65 years of age

  2. Individuals with a stable cervical spinal cord injury that have International Standards for the Neurological Classification of SCI (ISNCSCI) motor scores for fingers of 0 - 2 (non-functional) and ISNCSCI sensory scores of 0 - 2 (not normal) on the palmar side

  3. Individuals at least one year from initial spinal cord injury

  4. Individuals that are considered English Proficient due to the study requirements to follow verbal commands during testing sessions

  5. Individuals that are able to comprehend the study goals and procedures, and are able to provide informed consent for participation.

  6. Individuals that are willing and able to visit the study center for study procedures that will be 1-3 sessions a week for up to 12 months at 1-4 hours per session.

  7. Have the ability and willingness to undergo upper limb electrodiagnostic and nerve conduction studies

  8. Demonstrate typical amplitude, latency, and conduction velocity in the distal median, ulnar, and radial nerves of at least one upper limb

Exclusion Criteria:
  1. Individuals participating in another research study that may affect the conduct or results of this study

  2. Individuals having or exhibiting any of the following:

  3. Medical contraindications for diffusion tensor imaging, functional magnetic resonance imaging, electromyography, computed tomography, cortical stimulation, or craniotomies/surgeries

  4. Prior difficulties or allergy to general anesthesia

  5. Active wound healing or skin breakdown issues

  6. Stage III-IV pressure ulcers

  7. Chronically-implanted electronic medical device (e.g. baclofen pump, deep brain stimulator, epidural stimulator, cardiac pacemaker, vagus nerve stimulator, or other)

  8. Prior tendon transfer to enhance hand function

  9. History of autoimmune disease

  10. Cancer

  11. Biochemical abnormalities of the liver, kidney, or pancreas

  12. Ventilator dependence

  13. History of serious mood or thought disorder

  14. Significant residual clinically evident traumatic brain injury or cognitive impairment

  15. Uncontrolled autonomic dysreflexia

  16. Spasticity in the upper extremities that is uncontrolled by pharmacological methods

  17. Diagnosis of acute myocardial infarction or cardiac arrest within previous 6 months

  18. Individuals with any type of destruction and/or damage to the motor cortex region as determined by fMRI.

  19. History of a neurological ablation procedure

  20. History of hemorrhagic stroke

  21. History of infectious or chronic diseases, such as HIV or tuberculosis

  22. Individuals with any of the following co-morbid conditions that would interfere with study activities or response to treatment:

  23. Life expectancy < 3 years

  24. Severe chronic pulmonary disease

  25. Intractable seizure disorders

  26. Local, systemic acute or chronic infectious illness

  27. Life threatening cardiac arrhythmias

  28. Severe collagen vascular disorder

  29. Kidney failure or other major organ systems failures

  30. Individuals with a substance abuse (alcoholism or other) problem

  31. Pregnant women

  32. Prisoners

Contacts and Locations

Locations

Site City State Country Postal Code
1 Northwell Health's The Feinstein Institute for Medical Research Manhasset New York United States 11030

Sponsors and Collaborators

  • Chad Bouton

Investigators

  • Principal Investigator: Chad E Bouton, MS, Northwell Health

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
Chad Bouton, Vice President, Advanced Engineering; Managing Director, Center for Bioelectronic Medicine, Northwell Health
ClinicalTrials.gov Identifier:
NCT03680872
Other Study ID Numbers:
  • 17-0840
First Posted:
Sep 21, 2018
Last Update Posted:
Nov 23, 2021
Last Verified:
Nov 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Keywords provided by Chad Bouton, Vice President, Advanced Engineering; Managing Director, Center for Bioelectronic Medicine, Northwell Health
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 23, 2021